Inovio Pharmaceuticals Inc (INO)

NASDAQ
1.945
-0.095(-4.66%)
  • Volume:
    2,119,867
  • Day's Range:
    1.900 - 2.000
  • 52 wk Range:
    1.380 - 7.100

INO Overview

Prev. Close
2.04
Day's Range
1.9-2
Revenue
10.98M
Open
1.98
52 wk Range
1.38-7.1
EPS
-1.45
Volume
2,119,867
Market Cap
486.5M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
5,775,233
P/E Ratio
-1.33
Beta
1.01
1-Year Change
-71.82%
Shares Outstanding
249,489,264
Next Earnings Date
Mar 15, 2023
What is your sentiment on Inovio?
or
Vote to see community's results!

Inovio Pharmaceuticals Inc News

Inovio Pharmaceuticals Inc Analysis

Inovio Pharmaceuticals Inc Company Profile

Inovio Pharmaceuticals Inc Company Profile

Employees
317

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Read More

Analyst Price Target

Average2.250 (+14.80% Upside)
High3
Low2
Price1.96
No. of Analysts4
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellStrong Sell
Technical IndicatorsSellBuySellStrong SellStrong Sell
SummarySellNeutralStrong SellStrong SellStrong Sell
  • Big Day Emmett....Big Day !!!!
    0
    • Emmett Brown on a roll....up .05
      0
      • Nice Job Emmett
        0
        • Moderna up almost $13.00 today...Ino Up .04.......Great Job Quack Kim
          0
          • Dr. Emmet must be sleeping behind the wheel
            0
        • Moneypox, DNA based, 50 mutations so far.
          0
          • Another Banner day ahead ...Great Job Emmett
            0
            • Stellar Day Quack Pot
              0
              • Wow Quack Pot...back to even today
                0
                • Nice Day .....Ya BIG Quack
                  0
                  • Wow .....Up a whopping .03 after hours....You Show Them Fake Dr Kim.....QUACK QUACK QUACK
                    0